240 related articles for article (PubMed ID: 20805395)
1. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).
Zhanel GG; DeCorby M; Adam H; Mulvey MR; McCracken M; Lagacé-Wiens P; Nichol KA; Wierzbowski A; Baudry PJ; Tailor F; Karlowsky JA; Walkty A; Schweizer F; Johnson J; ; Hoban DJ
Antimicrob Agents Chemother; 2010 Nov; 54(11):4684-93. PubMed ID: 20805395
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Zhanel GG; DeCorby M; Laing N; Weshnoweski B; Vashisht R; Tailor F; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; McCracken M; Mulvey MR; Johnson J; ; Hoban DJ
Antimicrob Agents Chemother; 2008 Apr; 52(4):1430-7. PubMed ID: 18285482
[TBL] [Abstract][Full Text] [Related]
3. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
[TBL] [Abstract][Full Text] [Related]
4. Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16.
Lagacé-Wiens PRS; Adam HJ; Poutanen S; Baxter MR; Denisuik AJ; Golden AR; Nichol KA; Walkty A; Karlowsky JA; Mulvey MR; Golding G; Hoban DJ; Zhanel GG;
J Antimicrob Chemother; 2019 Aug; 74(Suppl 4):iv22-iv31. PubMed ID: 31505648
[TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
[TBL] [Abstract][Full Text] [Related]
6. [Antimicrobial susceptibility and prevalence of beta-lactamase producing clinical isolates in southern Kyushu. The results of collaborative study from 1999 to 2000].
Nakasone I; Onaga S; Fukunaga H; Saitoh H; Yamane N; Sato Y
Jpn J Antibiot; 2002 Sep; 55 Suppl A():95-110. PubMed ID: 12599533
[TBL] [Abstract][Full Text] [Related]
7. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
[TBL] [Abstract][Full Text] [Related]
8. Whole Genome Sequencing of Extended Spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae Isolated from Hospitalized Patients in KwaZulu-Natal, South Africa.
Founou RC; Founou LL; Allam M; Ismail A; Essack SY
Sci Rep; 2019 Apr; 9(1):6266. PubMed ID: 31000772
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study.
Zhanel GG; Adam HJ; Low DE; Blondeau J; Decorby M; Karlowsky JA; Weshnoweski B; Vashisht R; Wierzbowski A; Hoban DJ;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):291-306. PubMed ID: 21353957
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
[TBL] [Abstract][Full Text] [Related]
11. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
12. 42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.
Zhanel GG; Adam HJ; Baxter MR; Fuller J; Nichol KA; Denisuik AJ; Golden AR; Hink R; Lagacé-Wiens PRS; Walkty A; Mulvey MR; Schweizer F; Bay D; Hoban DJ; Karlowsky JA;
J Antimicrob Chemother; 2019 Aug; 74(Suppl 4):iv5-iv21. PubMed ID: 31505641
[TBL] [Abstract][Full Text] [Related]
13. Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.
Denisuik AJ; Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PRS; Mulvey MR; Hoban DJ; Zhanel GG;
J Antimicrob Chemother; 2019 Aug; 74(Suppl 4):iv64-iv71. PubMed ID: 31505647
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.
Denisuik AJ; Garbutt LA; Golden AR; Adam HJ; Baxter M; Nichol KA; Lagacé-Wiens P; Walkty AJ; Karlowsky JA; Hoban DJ; Mulvey MR; Zhanel GG
J Antimicrob Chemother; 2019 Mar; 74(3):645-653. PubMed ID: 30500898
[TBL] [Abstract][Full Text] [Related]
15. Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study (2005-2006).
Zhanel GG; Decorby M; Nichol KA; Baudry PJ; Karlowsky JA; Lagace-Wiens PR; McCracken M; Mulvey MR; Hoban DJ
Can J Infect Dis Med Microbiol; 2008 May; 19(3):243-9. PubMed ID: 19412382
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of methicillin resistant
Upreti N; Rayamajhee B; Sherchan SP; Choudhari MK; Banjara MR
Antimicrob Resist Infect Control; 2018; 7():121. PubMed ID: 30338059
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
Sader HS; Castanheira M; Jones RN; Flamm RK
Diagn Microbiol Infect Dis; 2017 Mar; 87(3):261-265. PubMed ID: 28069328
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of pathogen spectrum and antimicrobial resistance of pathogens associated with hospital-acquired infections collected from 11 teaching hospitals in 2018].
Li SG; Liao K; Su DH; Zhuo C; Chu YZ; Hu ZD; Xu XL; Zhang R; Liu WE; Lu BH; Zeng J; Jin Y; Wang H
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(47):3775-3783. PubMed ID: 33379842
[No Abstract] [Full Text] [Related]
19. Molecular characterization of multidrug-resistant ESKAPEE pathogens from clinical samples in Chonburi, Thailand (2017-2018).
Ruekit S; Srijan A; Serichantalergs O; Margulieux KR; Mc Gann P; Mills EG; Stribling WC; Pimsawat T; Kormanee R; Nakornchai S; Sakdinava C; Sukhchat P; Wojnarski M; Demons ST; Crawford JM; Lertsethtakarn P; Swierczewski BE
BMC Infect Dis; 2022 Aug; 22(1):695. PubMed ID: 35978294
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Vega S; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
